WO2005052137A1 - Tangential flow filtration devices and methods for stem cell enrichment - Google Patents
Tangential flow filtration devices and methods for stem cell enrichment Download PDFInfo
- Publication number
- WO2005052137A1 WO2005052137A1 PCT/US2004/038805 US2004038805W WO2005052137A1 WO 2005052137 A1 WO2005052137 A1 WO 2005052137A1 US 2004038805 W US2004038805 W US 2004038805W WO 2005052137 A1 WO2005052137 A1 WO 2005052137A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- cells
- sample
- filter
- cell
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 163
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000009295 crossflow filtration Methods 0.000 title claims abstract description 60
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 62
- 239000000470 constituent Substances 0.000 claims abstract description 54
- 210000004369 blood Anatomy 0.000 claims abstract description 52
- 239000008280 blood Substances 0.000 claims abstract description 52
- 238000000926 separation method Methods 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 150
- 239000012530 fluid Substances 0.000 claims description 75
- 238000001914 filtration Methods 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 53
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 46
- 210000001519 tissue Anatomy 0.000 claims description 36
- 239000011148 porous material Substances 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 210000000265 leukocyte Anatomy 0.000 claims description 23
- 210000003743 erythrocyte Anatomy 0.000 claims description 20
- 210000000056 organ Anatomy 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 12
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 12
- 238000004891 communication Methods 0.000 claims description 10
- 230000009089 cytolysis Effects 0.000 claims description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 210000003714 granulocyte Anatomy 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 210000005003 heart tissue Anatomy 0.000 claims description 4
- 230000001483 mobilizing effect Effects 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 230000001400 myeloablative effect Effects 0.000 claims description 2
- 230000003134 recirculating effect Effects 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 239000008241 heterogeneous mixture Substances 0.000 abstract description 7
- 239000012465 retentate Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000002245 particle Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 12
- 238000011084 recovery Methods 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 8
- 230000003394 haemopoietic effect Effects 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 6
- -1 bone marrow Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 3
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002579 anti-swelling effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D35/00—Filtering devices having features not specifically covered by groups B01D24/00 - B01D33/00, or for applications not specifically covered by groups B01D24/00 - B01D33/00; Auxiliary devices for filtration; Filter housing constructions
- B01D35/05—Floating filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004800346678A CN1886498B (en) | 2003-11-24 | 2004-11-19 | Tangential flow filtration devices and methods for stem cell enrichment |
CA2546349A CA2546349C (en) | 2003-11-24 | 2004-11-19 | Tangential flow filtration devices and methods for stem cell enrichment |
JP2006541397A JP2007512814A (en) | 2003-11-24 | 2004-11-19 | Tangential flow filtration device and method for stem cell enrichment |
AU2004293794A AU2004293794B2 (en) | 2003-11-24 | 2004-11-19 | Tangential flow filtration devices and methods for stem cell enrichment |
EP04811511A EP1689855A4 (en) | 2003-11-24 | 2004-11-19 | Tangential flow filtration devices and methods for stem cell enrichment |
BRPI0416898-4A BRPI0416898A (en) | 2003-11-24 | 2004-11-19 | tangential flow filtering devices and methods for stem cell enrichment |
IL175530A IL175530A (en) | 2003-11-24 | 2006-05-09 | Method for stem cell enrichment using a tangential flow filtration device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52451103P | 2003-11-24 | 2003-11-24 | |
US60/524,511 | 2003-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005052137A1 true WO2005052137A1 (en) | 2005-06-09 |
Family
ID=34632903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/038805 WO2005052137A1 (en) | 2003-11-24 | 2004-11-19 | Tangential flow filtration devices and methods for stem cell enrichment |
Country Status (14)
Country | Link |
---|---|
US (1) | US7790039B2 (en) |
EP (1) | EP1689855A4 (en) |
JP (2) | JP2007512814A (en) |
KR (1) | KR20070055416A (en) |
CN (2) | CN102321573B (en) |
AR (1) | AR047043A1 (en) |
AU (1) | AU2004293794B2 (en) |
BR (1) | BRPI0416898A (en) |
CA (1) | CA2546349C (en) |
CR (1) | CR8414A (en) |
IL (1) | IL175530A (en) |
RU (1) | RU2006122038A (en) |
TW (1) | TWI354572B (en) |
WO (1) | WO2005052137A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010002579A1 (en) * | 2008-06-30 | 2010-01-07 | General Electric Company | Bacteria/rna extraction device |
CN101851606A (en) * | 2010-04-07 | 2010-10-06 | 魏红江 | Cumulus oophorus-oocyte compound cutting filter method |
US8273253B2 (en) | 2007-03-02 | 2012-09-25 | Smith & Nephew Plc | Apparatus and method for filter cleaning by ultrasound, backwashing and filter movement during the filtration of biological samples |
EP2671600A1 (en) * | 2012-06-08 | 2013-12-11 | Pall Corporation | Cell harvesting device and system |
EP2699255A1 (en) * | 2011-04-21 | 2014-02-26 | Allergy Therapeutics (UK) Limited | Process for preparing vaccine composition |
WO2014093845A1 (en) * | 2012-12-14 | 2014-06-19 | Bhc Technology Holdings Llc | Point of care isolation and concentration of blood cells |
US9427512B2 (en) | 2012-06-08 | 2016-08-30 | Pall Corporation | Filter device |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010531142A (en) * | 2007-06-22 | 2010-09-24 | サークル バイオロジクス、 エルエルシー. | Liquid concentrator, autologous concentrated body fluid, and methods of use thereof |
KR100867942B1 (en) * | 2007-08-09 | 2008-11-10 | 콘티넨탈 오토모티브 일렉트로닉스 주식회사 | Lead frame structure of abs sensor for vehicle |
JP5330996B2 (en) * | 2007-08-23 | 2013-10-30 | 国立大学法人 新潟大学 | Human periosteum culture method |
FR2931081B1 (en) * | 2008-05-14 | 2010-06-25 | Direction Et Pirorites | DEVICE FOR FILTRATION OF A COMPLEX LIQUID SUCH AS BLOOD, IN PARTICULAR APPLICABLE TO AN AUTOSFUSER |
WO2010010355A2 (en) | 2008-07-25 | 2010-01-28 | Smith & Nephew Plc | Controller for separation apparatus |
RU2551778C2 (en) * | 2009-03-30 | 2015-05-27 | Дайити Санкио Компани, Лимитед | Method for inducing death of pluripotent stem cells and differentiated cells different from cardiomyocytes |
US20100291534A1 (en) * | 2009-05-12 | 2010-11-18 | National Central University | Methods and Systems for Isolating, Ex Vivo Expanding and Harvesting Hematopoietic Stem Cells |
CN105925535A (en) | 2009-06-05 | 2016-09-07 | 细胞动力国际有限公司 | Method Of Reprogramming T Cells And Hematopoietic Cells |
AU2013204820B2 (en) * | 2009-12-23 | 2014-01-30 | Cytovera, Inc. | A System and Method for Particle Filtration |
RU2539989C2 (en) | 2009-12-23 | 2015-01-27 | Сайтовера, Инк. | System and method for particle filtration |
CN102260628A (en) * | 2010-05-31 | 2011-11-30 | 上海康德莱企业发展集团医疗器械有限公司 | Device for filtering, screening, enriching and quick-compositing stem cells |
JP2012080821A (en) * | 2010-10-12 | 2012-04-26 | Univ Of Tsukuba | Method of concentrating nucleated cell component in blood |
CN102212461B (en) * | 2011-05-05 | 2013-04-17 | 中国人民解放军第二炮兵总医院 | Filter separator of mesenchyma stem cells and application thereof |
WO2012174225A2 (en) * | 2011-06-14 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Isolation, expansion and use of autologous pluripotent stem cells |
US10934519B2 (en) | 2011-07-29 | 2021-03-02 | Global Life Sciences Solutions Usa Llc | Systems, methods and control laws for cell harvesting |
PT2933326T (en) * | 2012-12-14 | 2021-06-17 | Chong Zheng | Centrifugal dynamic filtering apparatus and cell separation system using same |
SG11201505715RA (en) * | 2013-02-01 | 2015-08-28 | Ampio Pharmaceuticals Inc | Methods for producing diketopiperazines and compositions containing diketopiperazines |
JP2016518415A (en) * | 2013-10-21 | 2016-06-23 | アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー | Methods of repairing aging, disease immune dysfunction and cellular senescence with lymphoid stem cells, and methods of reapplying them for therapeutic use |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
CA2975726C (en) * | 2015-01-21 | 2022-03-15 | Agency For Science, Technology And Research | An isolated population of cell clusters and uses thereof |
CN105713870A (en) * | 2016-03-04 | 2016-06-29 | 佰通生物技术(苏州)有限公司 | Activation method for stem cells based on colony stimulating factor 1 |
CN110035702A (en) * | 2016-10-24 | 2019-07-19 | 耶鲁大学 | Sting device |
CN112342192B (en) * | 2020-10-27 | 2022-08-05 | 北京唐颐惠康生物医学技术有限公司 | Continuous tangential flow stem cell separation and purification method |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4420398A (en) | 1981-08-13 | 1983-12-13 | American National Red Cross | Filteration method for cell produced antiviral substances |
EP0208450A2 (en) | 1985-06-27 | 1987-01-14 | Apv Uk Limited | Beer filtration |
US4644056A (en) | 1984-09-06 | 1987-02-17 | Biotest Pharma Gmbh | Method of preparing a solution of lactic or colostric immunoglobulins or both and use thereof |
US5948441A (en) | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
US6313285B1 (en) * | 1999-07-23 | 2001-11-06 | Genentech, Inc. | Purification of plasmid DNA |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4240398A (en) * | 1978-10-05 | 1980-12-23 | Lindop Arthur H | Cleaning device for cooker grills |
US4888115A (en) | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
US4722902A (en) * | 1985-11-04 | 1988-02-02 | Endotronics, Inc. | Apparatus and method for culturing cells, removing waste and concentrating product |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5423738A (en) | 1992-03-13 | 1995-06-13 | Robinson; Thomas C. | Blood pumping and processing system |
NL9301653A (en) * | 1993-09-24 | 1995-04-18 | X Flow Bv | Method for removing turbidizing constituents from a liquid by microfiltration. |
US6984379B1 (en) * | 1994-04-08 | 2006-01-10 | Children's Hospital of LosAngeles | Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood |
US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US6140040A (en) * | 1995-10-06 | 2000-10-31 | Advanced Minerals Corporation | Method of mechanically separating microparticles suspended in fluids using particulate media |
AU708340B2 (en) * | 1995-10-23 | 1999-08-05 | Hemasure, Inc. | Extra-lumenal crossflow plasmapheresis devices |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US6177019B1 (en) * | 1996-08-26 | 2001-01-23 | Hemasure Inc. | Method and apparatus for removing tumor cells from tumor cell-contaminated stem cell products |
DE19650648A1 (en) * | 1996-12-06 | 1998-06-10 | Sartorius Gmbh | Winding module |
US6183640B1 (en) * | 1999-04-09 | 2001-02-06 | Usf Filtration And Separations Group, Inc. | Highly asymmetric anionic membranes |
CN1298949A (en) * | 1999-12-07 | 2001-06-13 | 刘宏宇 | Process for preparing human seralbumin from pichia pastoris |
US6544506B2 (en) * | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
JP2003525736A (en) * | 2000-03-07 | 2003-09-02 | エムアーテー アツォルプツィオーン テヒノロギース ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | Module with membrane element with cross flow and dead end configuration |
US6455306B1 (en) * | 2000-06-09 | 2002-09-24 | Transcyte, Inc. | Transfusable oxygenating composition |
JP4407996B2 (en) * | 2000-06-15 | 2010-02-03 | サンデン株式会社 | Coin dispensing device |
KR100809489B1 (en) * | 2001-10-10 | 2008-03-03 | 씨제이제일제당 (주) | 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
DE60237531D1 (en) * | 2001-10-11 | 2010-10-14 | Aviva Biosciences Corp | METHOD FOR DISCONNECTING RARE CELLS FROM FLUID SAMPLES |
JP2003320011A (en) * | 2002-04-30 | 2003-11-11 | Olympus Optical Co Ltd | Living tissue filling material, living tissue filling body, method of manufacturing living tissue filling body, and device of manufacturing living tissue filling body |
PT3173141T (en) * | 2002-06-19 | 2019-11-25 | Northwest Biotherapeutics Inc | Tangential flow filtration device and methods for leukocyte enrichment |
PL209998B1 (en) | 2003-02-27 | 2011-11-30 | Northwest Biotherapeutics Inc | Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines |
-
2004
- 2004-11-18 US US10/992,154 patent/US7790039B2/en active Active
- 2004-11-19 RU RU2006122038/13A patent/RU2006122038A/en not_active Application Discontinuation
- 2004-11-19 CN CN201110228728.6A patent/CN102321573B/en not_active Expired - Fee Related
- 2004-11-19 AU AU2004293794A patent/AU2004293794B2/en not_active Ceased
- 2004-11-19 EP EP04811511A patent/EP1689855A4/en not_active Withdrawn
- 2004-11-19 JP JP2006541397A patent/JP2007512814A/en active Pending
- 2004-11-19 WO PCT/US2004/038805 patent/WO2005052137A1/en active Application Filing
- 2004-11-19 BR BRPI0416898-4A patent/BRPI0416898A/en not_active IP Right Cessation
- 2004-11-19 CA CA2546349A patent/CA2546349C/en active Active
- 2004-11-19 CN CN2004800346678A patent/CN1886498B/en not_active Expired - Fee Related
- 2004-11-19 KR KR1020067012735A patent/KR20070055416A/en not_active Application Discontinuation
- 2004-11-24 TW TW093136123A patent/TWI354572B/en not_active IP Right Cessation
- 2004-11-24 AR ARP040104354A patent/AR047043A1/en not_active Application Discontinuation
-
2006
- 2006-05-09 IL IL175530A patent/IL175530A/en active IP Right Grant
- 2006-05-22 CR CR8414A patent/CR8414A/en not_active Application Discontinuation
-
2011
- 2011-06-28 JP JP2011143589A patent/JP5343110B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4420398A (en) | 1981-08-13 | 1983-12-13 | American National Red Cross | Filteration method for cell produced antiviral substances |
US4644056A (en) | 1984-09-06 | 1987-02-17 | Biotest Pharma Gmbh | Method of preparing a solution of lactic or colostric immunoglobulins or both and use thereof |
EP0208450A2 (en) | 1985-06-27 | 1987-01-14 | Apv Uk Limited | Beer filtration |
US5948441A (en) | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
US6313285B1 (en) * | 1999-07-23 | 2001-11-06 | Genentech, Inc. | Purification of plasmid DNA |
Non-Patent Citations (3)
Title |
---|
QUIRK ET AL., ENZYME MICROB TECHNO, vol. 6, 1984, pages 201 |
RADLETT, J APPL CHEM BIOTECHNOL., vol. 22, 1972, pages 495 |
See also references of EP1689855A4 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8273253B2 (en) | 2007-03-02 | 2012-09-25 | Smith & Nephew Plc | Apparatus and method for filter cleaning by ultrasound, backwashing and filter movement during the filtration of biological samples |
WO2010002579A1 (en) * | 2008-06-30 | 2010-01-07 | General Electric Company | Bacteria/rna extraction device |
US8546127B2 (en) | 2008-06-30 | 2013-10-01 | General Electric Company | Bacteria/RNA extraction device |
CN101851606A (en) * | 2010-04-07 | 2010-10-06 | 魏红江 | Cumulus oophorus-oocyte compound cutting filter method |
EP2699255A1 (en) * | 2011-04-21 | 2014-02-26 | Allergy Therapeutics (UK) Limited | Process for preparing vaccine composition |
EP2699255B1 (en) * | 2011-04-21 | 2016-11-02 | Allergy Therapeutics (UK) Limited | Process for preparing vaccine composition |
AU2012246087B2 (en) * | 2011-04-21 | 2017-05-18 | Allergy Therapeutics (Uk) Limited | Process for preparing vaccine composition |
US9731004B2 (en) | 2011-04-21 | 2017-08-15 | Allergy Therapeutics (Uk) Limited | Process for preparing vaccine composition |
EP2671600A1 (en) * | 2012-06-08 | 2013-12-11 | Pall Corporation | Cell harvesting device and system |
US9421317B2 (en) | 2012-06-08 | 2016-08-23 | Pall Corporation | Cell harvesting device and system |
US9427512B2 (en) | 2012-06-08 | 2016-08-30 | Pall Corporation | Filter device |
WO2014093845A1 (en) * | 2012-12-14 | 2014-06-19 | Bhc Technology Holdings Llc | Point of care isolation and concentration of blood cells |
Also Published As
Publication number | Publication date |
---|---|
CR8414A (en) | 2006-11-23 |
IL175530A0 (en) | 2006-09-05 |
US7790039B2 (en) | 2010-09-07 |
EP1689855A4 (en) | 2008-04-16 |
EP1689855A1 (en) | 2006-08-16 |
CN1886498B (en) | 2013-10-30 |
AU2004293794A1 (en) | 2005-06-09 |
JP5343110B2 (en) | 2013-11-13 |
CN102321573A (en) | 2012-01-18 |
IL175530A (en) | 2012-07-31 |
JP2011182803A (en) | 2011-09-22 |
TWI354572B (en) | 2011-12-21 |
CA2546349A1 (en) | 2005-06-09 |
AU2004293794B2 (en) | 2011-06-02 |
BRPI0416898A (en) | 2007-03-06 |
US20050189297A1 (en) | 2005-09-01 |
RU2006122038A (en) | 2008-01-10 |
JP2007512814A (en) | 2007-05-24 |
AR047043A1 (en) | 2006-01-04 |
CN102321573B (en) | 2015-01-14 |
CA2546349C (en) | 2015-07-07 |
CN1886498A (en) | 2006-12-27 |
TW200524647A (en) | 2005-08-01 |
KR20070055416A (en) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7790039B2 (en) | Tangential flow filtration devices and methods for stem cell enrichment | |
EP2298436B1 (en) | Use of a tangential flow filtration device and methods for leukocyte enrichment | |
US20040152190A1 (en) | Method of separating and concentrating cells for kidney regfneration | |
AU2011218747B2 (en) | Tangential flow filtration devices and methods for stem cell enrichment | |
MXPA06005885A (en) | Tangential flow filtration devices and methods for stem cell enrichment | |
JP4333936B2 (en) | Method for obtaining cells for regeneration of living bone tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480034667.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 175530 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2546349 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 547218 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006541397 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004293794 Country of ref document: AU Ref document number: 2004811511 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2006-008414 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/005885 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2004293794 Country of ref document: AU Date of ref document: 20041119 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004293794 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067012735 Country of ref document: KR Ref document number: 2282/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006122038 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004811511 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0416898 Country of ref document: BR |